NCT04450303

Brief Summary

The COVID-19 pandemic has substantially increased the risk of adverse mental health outcomes; while physical distancing is required to reduce infection risk, it also increases loneliness and isolation and prevents access to traditional in-person therapy, which further contribute to risk of adverse mental health outcomes. These problems may be especially acute for individuals with social anxiety disorder (as many as 12% of Americans), however there is a limited evidence-base for telehealth options to directly address social anxiety. This project aims to adapt exposure therapy for social anxiety to a telehealth and physical distancing-compatible intervention, and test whether this effectively decreases loneliness in adults with elevated social anxiety.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 24, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 29, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

October 30, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 2, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 2, 2021

Completed
Last Updated

September 23, 2021

Status Verified

September 1, 2021

Enrollment Period

7 months

First QC Date

June 24, 2020

Last Update Submit

September 21, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Liebowitz Social Anxiety Scale (LSAS)

    Social anxiety severity, lower scores are better (indicating less anxiety). Minimum score is 0, maximum score is 144.

    12 weeks

  • Satisfaction with Therapy and Therapists Scale (STTS)

    Therapy satisfaction subscale, higher scores are better (indicating greater satisfaction). Minimum score is 6, maximum score is 30.

    12 weeks

  • UCLA Loneliness Scale version 3

    Loneliness, lower scores are better (indicating less loneliness). Minimum score is 20, maximum score is 80.

    12 weeks

Secondary Outcomes (2)

  • Liebowitz Social Anxiety Scale (LSAS)

    24 weeks

  • UCLA Loneliness Scale version 3

    24 weeks

Study Arms (1)

Telehealth Therapy

EXPERIMENTAL
Behavioral: Telehealth CBT

Interventions

Telehealth CBTBEHAVIORAL

The Coordinated Anxiety Learning and Management (CALM) program is an evidence-based, computer-assisted protocol for cognitive behavioral therapy (CBT) for anxiety, depression, and/or post-traumatic stress. CALM will be implemented via secure and HIPAA compliant video-conferencing software (enterprise Zoom), following modifications to address obstacles associated with physical distancing and the tele-health medium.

Also known as: CALM
Telehealth Therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18+,
  • Liebowitz Social Anxiety Scale (LSAS) total score \> 50
  • Fluent spoken and written English
  • Access to the internet via a smartphone or computer with a camera
  • Ability to provide informed consent.

You may not qualify if:

  • History of mania or psychosis
  • Moderate or severe substance use disorder within the past year
  • Current psychiatric diagnosis of greater impairment than that arising from social anxiety
  • High risk for suicide (\>8 on the Mini International Neuropsychiatric Interview suicidality section)
  • Prior exposure therapy (more than 2 sessions)
  • Current psychotropic medication use
  • Current psychotherapy other than couples counseling.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University

Stanford, California, 94304, United States

Location

Study Officials

  • Tali Ball, PhD

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Instructor

Study Record Dates

First Submitted

June 24, 2020

First Posted

June 29, 2020

Study Start

October 30, 2020

Primary Completion

June 2, 2021

Study Completion

June 2, 2021

Last Updated

September 23, 2021

Record last verified: 2021-09

Locations